Vaginal Immunization to Elicit Primary T-Cell Activation and Dissemination

Elena Pettini¹, Gennaro Prota¹, Annalisa Ciabattini¹, Alessandro Boianelli², Fabio Fiorino¹, Gianni Pozzi¹, Antonio Vicino², Donata Medaglini¹*¹

¹Laboratorio di Microbiologia Molecolare e Biotecnologia (LAMMB), Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy, ²Dipartimento di Ingegneria dell’Informazione (DII), Centro per lo Studio dei Sistemi Complessi (CSC), Università di Siena, Siena, Italy

Abstract

Primary T-cell activation at mucosal sites is of utmost importance for the development of vaccination strategies. T-cell priming after vaginal immunization, with ovalbumin and CpG oligodeoxynucleotide adjuvant as model vaccine formulation, was studied in vivo in hormone-synchronized mice and compared to the one induced by the nasal route. Twenty-four hours after both vaginal or nasal immunization, antigen-loaded dendritic cells were detected within the respective draining lymph nodes. Vaginal immunization elicited a strong recruitment of antigen-specific CD4+ T cells into draining lymph nodes that was more rapid than the one observed following nasal immunization. T-cell clonal expansion was first detected in iliac lymph nodes, draining the genital tract, and proliferated T cells disseminated towards distal lymph nodes and spleen similarly to what observed following nasal immunization. T cells were indeed activated by the antigen encounter and acquired homing molecules essential to disseminate towards distal lymphoid organs as confirmed by the modulation of CD45RB, CD69, CD44 and CD62L marker expression. A multi-type Galton Watson branching process, previously used for in vitro analysis of T-cell proliferation, was applied to model in vivo CFSE proliferation data in draining lymph nodes 57 hours following immunization, in order to calculate the probabilistic decision of a cell to enter in division, rest in quiescence or migrate/die. The modelling analysis indicated that the probability of a cell to proliferate was higher following vaginal than nasal immunization. All together these data show that vaginal immunization, despite the absence of an organized mucosal associated inductive site in the genital tract, is very efficient in priming antigen-specific CD4+ T cells and inducing their dissemination from draining lymph nodes towards distal lymphoid organs.

Citation: Pettini E, Prota G, Ciabattini A, Boianelli A, Fiorino F, et al. (2013) Vaginal Immunization to Elicit Primary T-Cell Activation and Dissemination. PLoS ONE 8(12): e80545. doi:10.1371/journal.pone.0080545

Editor: Roger Le Grand, Commissariat a l’Energie Atomique(cea), France

Received August 9, 2013; Accepted October 14, 2013; Published December 5, 2013

Copyright: © 2013 Pettini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study has been carried out with the financial support from the Commission of the European Communities, Seventh Framework Programme contract 280873 Advanced Immunisation Technologies (ADITEC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: donata.medaglini@unisi.it

Introduction

T-cell priming at mucosal sites is of primary importance for the development of mucosal vaccine formulations and prime-boost strategies aimed to elicit mucosal and systemic effector immune responses. Despite the many attractive features of mucosal vaccination, only few vaccines approved for human use are currently administered mucosally, and they are all based on live attenuated microorganisms with none on subunit of pathogens [1–4]. To advance the development of new mucosal vaccines, not only appropriate antigens, adjuvants and delivery systems but also proper mucosal routes of administration should be deeply characterised [1,5–7].

The induction of mucosal immune responses requires the presence of a mucosa-associated lymphoid tissue that provides a continuous source of B and T cells to mucosal effector sites [8]. Inductive sites for mucosal immunity consist of organized mucosa-associated lymphoid tissue as well as local and regional draining lymph nodes (LNs), whereas the effector sites include distinctly different histological compartments, mainly consisting of the lamina propria of various mucosae [9]. Inductive sites in the gastro-intestinal and respiratory tracts have been well defined and are composed of aggregated lymphoid tissues (gut-, nasal- and bronchial-associated lymphoid tissues respectively) and mucosa-associated lymph nodes (mesenteric and mediastinal lymph nodes), on the contrary the vaginal mucosa is devoid of histologically demonstrable organised mucosa-associated lymphoid tissue and the role of inductive site is played directly by draining iliac lymph nodes [5].

Female genital tract has therefore some unique features that should be taken in consideration in the development of vaccination strategies. Following vaginal immunization T-cell priming occurs in the iliac lymph nodes from which T and B cells migrate to the effector sites [5,6,10–12]. Antigens are sampled from the vaginal lumen by macrophages and dendritic cells (DCs) that then move towards draining iliac lymph nodes. Antigen-uptake across the vaginal mucosa barrier and immune responses in the genital tract are greatly regulated and influenced by the hormonal state and estrus phase [13–16]. Sex hormones also affect the migration of macrophages and DCs as well as T and B cells by involving the expression of adhesion molecules and chemotactic factors [17]. In particular, there are indications that estradiol, which induces an estrus-like state, inhibits T-cell priming
Indeed, the process with immigration to model T-cell proliferation at different time points. We adopted a multi-type branching process to study the distribution of OVA-bearing DCs at early time points. As an example, for studying T-cell primary activation following vaginal or nasal immunization in vivo after adoptive transfer of OVA-specific CD4+ T cells, progesterone treated C57BL/6J mice were irradiated with 200 rads before intravenous injection of 2.5 × 10⁶ of CFSE-labelled T cells, followed by vaginal or nasal route immunisation with the fluorescent OVA (grade V, Sigma-Aldrich) (0.1 mg/mouse). The stage of estrus was confirmed by vaginal smear. OVA uptake was tracked in vivo using ovalbumin-Alexa fluoro 488 conjugate (Invitrogen Molecular Probes, Eugene, OR, USA). C57BL/6J mice were lightly anaesthetized by intraperitoneal injection of tiletamine, zolazepam hydrochloride (Zoletil 20, Laboratoires Virbac, France, 6 mg/kg) and xylazine (Xilor 2%, Bio 98 Srl, Italy, 3 mg/kg), and immunized by vaginal or nasal route with the fluorescent OVA (25 μg/mouse) mixed with the mucosal adjuvant CpG ODN 1826 (TCC ATG ACG TTC CTG ACG TT, Eurofins MWG Operon, Ebersberg, Germany) (20 μg/mouse). Mice immunized by vaginal route were housed in single cages and equipped with a collar for some hours to avoid self-sniffing.

Groups of four animals were sacrificed 12, 24 and 72 hours after mucosal immunisation. Iliac (subiliac, medial and external), cervical (superficial and posterior) lymph nodes and spleen were harvested and digested in Click's medium (Sigma-Aldrich) (0.1 mg/mouse). The stage of estrus was confirmed by vaginal smear. OVA uptake was tracked in vivo using ovalbumin-Alexa fluoro 488 conjugate (Invitrogen Molecular Probes, Eugene, OR, USA). C57BL/6J mice were lightly anaesthetized by intraperitoneal injection of tiletamine, zolazepam hydrochloride (Zoletil 20, Laboratoires Virbac, France, 6 mg/kg) and xylazine (Xilor 2%, Bio 98 Srl, Italy, 3 mg/kg), and immunised by vaginal or nasal route with the fluorescent OVA (25 μg/mouse) mixed with the mucosal adjuvant CpG ODN 1826 (TCC ATG ACG TTC CTG ACG TT, Eurofins MWG Operon, Ebersberg, Germany) (20 μg/mouse). Mice immunized by vaginal route were housed in single cages and equipped with a collar for some hours to avoid self-sniffing.

Groups of four animals were sacrificed 12, 24 and 72 hours after mucosal immunisation. Iliac (subiliac, medial and external), cervical (superficial and posterior) lymph nodes and spleen were harvested and digested in Click's medium (Sigma-Aldrich) with 2 mg/ml of Collagenase D (Roche Applied Science, Penzberg, Germany) for 30 min at 37°C. Organs were mashed onto nylon screens (Sefar Italia, Italy) and washed in PBS with 0.5% of bovine serum albumin (BSA, Sigma-Aldrich) and 2 mM EDTA (Malininckrodt Baker, Philadelphia, NJ, USA).

Adoptive transfer of transgenic CD4+ T cells

Single cell suspensions from the spleen and pooled lymph nodes (cervical, brachial, axillary, mesenteric and iliac) of OT-II transgenic mice were enriched for CD4+ T cells, by negative selection using the EasySep magnetic nanoparticles (StemCell Technologies, Vancouver, BC, Canada), according to the manufacturer’s protocol. The purity of the CD4+ T-cell population in the enriched fraction was >95%, as determined by flow cytometric analysis. OT-II transgenic CD4+ T cells were stained with CFSE (7.5 μM, Invitrogen) [43], for 10 min at 37°C. An amount of 2.5 × 10⁶ of CFSE-labelled T cells were injected into the tail vein of each recipient mouse.

Vaginal and nasal immunization of mice and sample collection

Twenty-four hours after adoptive transfer of CFSE-labelled OT-II CD4+ T cells, progesterone treated G57BL/6J mice were vaginally or nasally immunized with OVA grade V (Sigma-Aldrich) (25 μg/mouse) and CpG ODN 1826 (20 μg/mouse).
Mice were lightly anaesthetized by intraperitoneal injection and then inoculated with OVA and CpG into the vagina or into nostrils with a volume of 15 μl. Mice immunized by vaginal route were housed individually and equipped with a collar for some hours to avoid self-sniffing.

Groups of six mice were sacrificed 0, 48, 57, 72, 120 and 168 hours following immunization. Iliac, cervical lymph nodes and spleen were individually harvested from each mouse. Single-cell suspensions from cervical, iliac lymph nodes and spleens were obtained as previously described [29].

In other experiments, purified anti-CD62L (MEL-14, Southern Biotechnology, USA) was administered intravenously at 100 μg/mouse 6 h after immunization with OVA plus CpG ODN1826 and then every 24 h until harvest. Fifty-seven hours after mouse 6 h after immunization with OVA plus CpG ODN1826.

Flow cytometric analysis

Cells suspensions from lymph nodes and spleens were incubated with Fc-blocking solution [0.5 mg CD16/CD32 mAb (clone 93) (eBioscience, USA), 5% mouse serum, 5% rat serum, 0.2% sodium azide (all from Sigma-Aldrich) in 100 ml of HBSS] for 30 min at 4°C. T cells were stained with PerCP-conjugated anti-mouse CD4 (clone RM 4-5) (BD Pharmingen), APC-conjugated anti-mouse CD44 (clone IM7), CD45RB (clone M5/114.15.2) or CD62L PE-conjugated (all from eBioscience) for 30 min at 4°C.

For DCs studies, cells were labelled with eFluor 710-conjugated I-A/I-E (clone M5/114.15.2) and anti-mouse CD11c PE-conjugated (clone N418) (all from eBioscience).

CountBright absolute counting beads (Invitrogen, Molecular Probes, Oregon, USA) were used for counting the number of lymphocytes in each sample. All samples were analyzed by flow cytometry (FACScalibur, Becton Dickinson, San Diego, CA). Data analysis was performed by using FlowJo software (Tree Star, Ashland, OR, USA).

Statistical analysis

The number of proliferating T cells in lymph nodes and spleen was analysed individually and values were expressed as mean ± standard error of the mean (SEM).

Statistical differences between the quantity of antigen-specific transgenic T cells detected in lymphoid organs at different time points were assessed using one-way analysis of variance (ANOVA) and Tukey’s post test for multiple comparisons. Statistical significance was defined as P<0.05. Graphpad 4.0 software was used for analysis.

Mathematical model and assumptions

A multi-type Galton Watson (MGW) branching process was used to model in vivo CFSE proliferation data. The key assumptions featuring MGW models are: 1) each cell action is independent from others; 2) each dividing cell generates its own branching process; 3) the cell has no memory about previous time-steps (Markovian process) [37,44,45].

During each time-step Δt, it is assumed that a single cell in generation i, i = 0,..., p (where p is the highest number of cell generation tracked by flow cytometry), can divide with probability γi into two i+1 generation cells, rest in its generation i with probability δi, or die/migrate with probability ζi. Of course, 2 out of the 3 probability parameters can vary independently, e.g. δi and γi, being ζi=1−δi−γi. We assume that the process has distinct probability parameters for cells in generations 0, 1, 2 [36], while probabilities for generations i>2 are assumed equal to those of generation i = 2. The MGW process is then specified by μ̂ the choice of the time-step Δt, i) the initial cell number in generation 0 and μ̂ the vector of parameters that determine the probabilities for each cell generation, i.e., μ̂=[b0, b1, δ1, γ1, δ2, γ2]T. For this process, we can define the first and second order moments, i.e. the mean and covariance matrix of live cells counts at each time-point t, which in turn, can be exploited to compute the Maximum Likelihood function for the estimation problem of the parameter μ̂ [39].

However, in vivo experiments shown at least two factors which violate the classical hypothesis on MGW models and the related inferences from experimental data, requiring specific modeling interventions. We outline below these items and the actions taken to overcome them:

1) The draining site is not ‘isolated’ with respect to other lymph nodes. This means that the cell proliferation process may be seriously affected by migration from and to other distal lymph nodes. In this case, the process division, death and quiescence rates are biased, and it is not true anymore that their sum is 1.

2) All the in vivo experiments require animal sacrifice to collect CFSE data. This means that measurements taken at different time points actually refer to different individuals. This fact introduces an inter-individual stochastic aspect which is not considered in classical inference schemes.

With reference to the first issue, the impact of T-cell egress has been ruled out, because the measurements, used for inference, were carried out at early time points when most of primed T cells have not left the draining lymph node. On the contrary, it is well known that a significant entry phenomenon of naïve T cells takes place over the measurement time horizon, due to the recruitment of T cells from other lymphoid sites. This problem has been solved by using a 2 stage procedure. First, the pure MGW model (with isolated draining lymph node) is exploited to compute the probability parameters on an appropriate experiment, where access is blocked through the treatment with the anti-CD62L antibody (see section on Results). Second, the MGW model is generalized by adding an immigration term r [46] to the naïve T cell population in the draining site. The generalized model can be estimated by using the experimental data and exploiting the MGW model used in the first stage.

Regarding the intrinsic difficulties of the second issue, model identification has been performed by using relative frequencies as model variables instead of cell counts. Relative frequency was calculated as the percentage of OVA-specific CD4+ CFSE+ T cells present in each generation towards the total number of OVA-specific CD4+ T cells present in the lymph node. This choice allows us to derive an explicit expression for the Maximum Likelihood function for the MGW model, since the distribution of relative frequencies at different time points is asymptotically normal, and the number of initial cells starting the proliferation process is large [39]. In order to derive estimates ū and ̄r for the ū and ̄r MGW model parameters, we constructed the following iterative estimation procedure. We assume that an initial estimate of the MGW model u = û0 is available and proceed with the following steps: i) compute the mean value of T-cell counts of the MGW model used in the first stage.

Regarding the intrinsic difficulties of the second issue, model identification has been performed by using relative frequencies as model variables instead of cell counts. Relative frequency was calculated as the percentage of OVA-specific CD4+ CFSE+ T cells present in each generation towards the total number of OVA-specific CD4+ T cells present in the lymph node. This choice allows us to derive an explicit expression for the Maximum Likelihood function for the MGW model, since the distribution of relative frequencies at different time points is asymptotically normal, and the number of initial cells starting the proliferation process is large [39]. In order to derive estimates ū and ̄r for the ū and ̄r MGW model parameters, we constructed the following iterative estimation procedure. We assume that an initial estimate of the MGW model u = û0 is available and proceed with the following steps: i) compute the mean value of T-cell counts of the MGW model used in the first stage.

Regarding the intrinsic difficulties of the second issue, model identification has been performed by using relative frequencies as model variables instead of cell counts. Relative frequency was calculated as the percentage of OVA-specific CD4+ CFSE+ T cells present in each generation towards the total number of OVA-specific CD4+ T cells present in the lymph node. This choice allows us to derive an explicit expression for the Maximum Likelihood function for the MGW model, since the distribution of relative frequencies at different time points is asymptotically normal, and the number of initial cells starting the proliferation process is large [39]. In order to derive estimates ū and ̄r for the ū and ̄r MGW model parameters, we constructed the following iterative estimation procedure. We assume that an initial estimate of the MGW model u = û0 is available and proceed with the following steps: i) compute the mean value of T-cell counts of the MGW model used in the first stage.

Regarding the intrinsic difficulties of the second issue, model identification has been performed by using relative frequencies as model variables instead of cell counts. Relative frequency was calculated as the percentage of OVA-specific CD4+ CFSE+ T cells present in each generation towards the total number of OVA-specific CD4+ T cells present in the lymph node. This choice allows us to derive an explicit expression for the Maximum Likelihood function for the MGW model, since the distribution of relative frequencies at different time points is asymptotically normal, and the number of initial cells starting the proliferation process is large [39]. In order to derive estimates ū and ̄r for the ū and ̄r MGW model parameters, we constructed the following iterative estimation procedure. We assume that an initial estimate of the MGW model u = û0 is available and proceed with the following steps: i) compute the mean value of T-cell counts of the MGW model used in the first stage.

Regarding the intrinsic difficulties of the second issue, model identification has been performed by using relative frequencies as model variables instead of cell counts. Relative frequency was calculated as the percentage of OVA-specific CD4+ CFSE+ T cells present in each generation towards the total number of OVA-specific CD4+ T cells present in the lymph node. This choice allows us to derive an explicit expression for the Maximum Likelihood function for the MGW model, since the distribution of relative frequencies at different time points is asymptotically normal, and the number of initial cells starting the proliferation process is large [39]. In order to derive estimates ū and ̄r for the ū and ̄r MGW model parameters, we constructed the following iterative estimation procedure. We assume that an initial estimate of the MGW model u = û0 is available and proceed with the following steps: i) compute the mean value of T-cell counts of the MGW model used in the first stage.
Results

Antigen-loaded DCs are localized in draining lymph nodes

The localization of antigen-loaded DCs was assessed after vaginal and nasal administration of the vaccine model formulation. To this aim mice were inoculated vaginally or nasally with OVA-Alexa Fluor 647 conjugate and the mucosal adjuvant CpG ODN 1826. Mice were pre-treated with progesterone in order to synchronize the estrous cycle to the diestrus phase and to facilitate antigen-uptake. Antigen loading was analyzed following vaginal or nasal immunization in draining lymph nodes (ilac and cervical lymph nodes respectively), in distal lymph nodes (cervical and iliac lymph nodes, respectively) and in the spleen. The presence of antigen-loaded DCs in lymphoid sites was assessed 0, 12, 24 and 72 hours after the inoculum. Within the first day after the immunization, antigen-loaded DCs (CD11c+ MHC class II+ cells) were localized only in the respective draining lymph nodes, with about 6% and 4% of DCs detected following vaginal and nasal immunization respectively (Fig. 1A and B). On the contrary, in distal lymph nodes and in the spleen, antigen-loaded DCs were not detected at any time point (Fig. 1A and B), indicating that also following vaginal immunization antigen presentation occurs within lymph nodes draining the immunization site, and not in other lymphoid sites, in accordance with what was observed and previously reported for nasal immunization [32]. No significant differences in the number of antigen-loaded DCs were indeed observed between vaginally and nasally immunized mice. These data show that the antigen-uptake following vaginal immunization of progesterone-treated mice was as efficient as the one observed following nasal immunization.

Vaginal immunization elicits a rapid recruitment and clonal expansion of CD4+ T cells in draining lymph nodes

To characterize T-cell clonal expansion and distribution, OVA-specific transgenic CD4+ T cells, labeled with CFSE, were adoptively transferred into recipient mice that were immunized with the model formulation OVA and CpG ODN 1826 by the vaginal or nasal route. The distribution of OVA-specific transgenic T cells in adoptively transferred recipient mice was assessed in draining and distal lymph nodes and spleen, 57 and 72 hours after immunization and compared with the one detected at the time the antigenic stimulus was given (time 0) [47] (Table 1). Following vaginal immunization was observed a 5-fold increase of antigen-specific CD4+ T cells in draining iliac lymph nodes at 57 hours (Fig. 2 and Table 1), and a 7-fold increase at 72 hours (1×10^5 OVA-specific CD4+ T cells respect to 1.6×10^4 at time 0; P<0.001; Table 1). The amount of total lymphocytes also increased gradually from time 0 to 72 hours, suggesting a general recruitment of lymphocytes from other lymphoid sites (Table 1). On the contrary, in distal cervical lymph nodes, a 4-fold decrease was detected at 57 hours (8.8×10^3 respect to 3×10^4 at time 0; P<0.05; Table 1 and Fig. 2). The distribution of the antigen-specific T cells described was comparable to the one observed following nasal immunization, where the recruitment of antigen-specific T cells into draining sites appeared slower with a 3-fold increase observed at 72 hours (8×10^4 respect to 2×10^5 at time 0; P<0.05; Table 1 and Fig. 2) while, a drastic reduction of antigen-specific T-cell number was detected in distal iliac lymph nodes already 57 hours after immunization (1.7×10^3 respect to 1.5×10^4 at time 0; P<0.001; Table 1 and Fig. 2). In the spleen, a 3-fold decrease of antigen-specific T-cell was observed 57 hours following both vaginal and nasal immunization (Fig. 2), probably due to CD4+ T-cell recruitment in draining lymph nodes, while antigen-specific T-cell numbers were reestablished at 72 hours (Table 1). These data demonstrate a strong recruitment of antigen-specific T cells into the lymph nodes draining the immunization site, that was more rapid following vaginal than nasal immunization.

Fifty-seven hours following immunization of progesterone treated mice, antigen-specific T cells initiated their clonal expansion within draining lymph nodes, as identified by CFSE dilution (Fig. 3). Five cell generations were detectable in iliac lymph nodes of vaginally immunized mice and 4 major in cervical lymph nodes of nasally immunized mice (Fig. 3). The presence of an additional peak in vaginally immunized mice is consistent with the observed more rapid T-cell recruitment. On the contrary, no T-cell proliferation was observed in estrogen treated mice, since antigen-uptake does not occur in the vaginal tissue in the estrous phase, confirming the hormonal dependence of T-cell priming in the genital tract [19]. Untreated animals maintained a high level of CFSE fluorescence in lymph nodes, indicating that no cell division occurred (Fig. 3).

CFSE proliferation data were analysed using mathematical model based on Mutlt-type Galton Watson branching process

A mathematical model based on the MGW branching process with immigration was adopted to analyse antigen-specific CD4+ T-cell proliferation data in draining lymph nodes following vaginal and nasal immunization. During each time-step it is assumed that a single cell in generation i, can make three independent probabilistic choices: divide with probability $\gamma_i$, into two $i+1$ generation cells, rest in its generation $i$ with probability $\delta_i$ or die/ migrate with probability $\omega_i$. A schematic representation of this process is reported in Fig. 4A.

Since a lymph node is not an ‘isolated’ site but it is a component of the complex immunologic network including different lymphoid sites, T-cell proliferation process may be influenced by the immigration from and the migration to distal lymph nodes with a consequent bias on the division, death and quiescence rates. In our case the migration component was excluded since measurements were carried out at the time point (57 h) when most of primed T cells have not left the draining lymph nodes. The continuous recruitment of naive T cells into draining lymph nodes from other lymphoid organs was considered by introducing an ‘immigration’ additive term in the MGW model, represented by a parameter $\iota$, that indicates the number of naive T cells entering the draining lymph node during each time step (immigration parameter). We assumed as initial cell number, the amount of antigen-specific T cells detected in a lymphoid organ at the time when the antigenic stimulus was given [47]. The starting time point for the counting process ($n=0$) was fixed at $t=42$ hours, the time that is considered as the average time when a cell begins to divide. The model time step was chosen as $\Delta t=3$ hours based on the assessment that three new cell generations were observed in draining lymph nodes between 48 and 57 hours following vaginal and nasal immunization (data not shown). Different probability parameters were assumed for generations $i=0$, 1 and 2 while parameters for generations $>2$ were assumed equal to those for $i=2$ [36]. A Maximum Likelihood approach was adopted to estimate model parameters including both the probability and the immigration parameters. The parameters were estimated on the number of OVA-specific CD4+ T cells in each cell generation, reported as a relative frequency (percentage of CD4+ CFSE+ cells per absolute number of lymphocytes/100). Data from a total of 20 animals immunized by the vaginal or nasal route and sacrificed at time 0 or 57 were used for the model analysis. To improve the estimate quality, an additional experiment was performed blocking
T-cell entry into lymph nodes and providing data useful for an initial evaluation of the probability parameters ($u^0$ in Material and Methods Section). In this experiment, mice, previously adoptively transferred with OVA-specific CD4$^+$ T cells, were immunized with OVA and CpG ODN and daily treated with anti-CD62L antibody. As shown in Figure 4B, the anti-CD62L antibody treatment prevented the entry of naive antigen-specific T cells within the draining lymph nodes.

The estimated immigration parameter $\tilde{r}$ was 3280 following vaginal immunization and 915 following the nasal route. The probability parameter vector $u$ and the corresponding standard deviations obtained from analyzing T-cell proliferation following vaginal and nasal immunization are reported in Table 2. The parameters were estimated for undivided cells ($d_0$ and $c_0$), first generation ($d_1$ and $c_1$) and second and subsequent generations ($d_2$ and $c_2$). The values of parameters $c_i$, representing the probability of a cell to proliferate, calculated for $i = 0, 1, 2$ increased with increasing number of cell generations and were higher following vaginal than nasal immunisation. At the same time, the parameters $d_i$, representing the probability of a cell to rest in the same generation, were lower for vaginal than nasal immunisation. These data suggest that after vaginal immunisation antigen-specific T cells rapidly increase their ability to divide with increasing number of cell divisions. Moreover, the parameters $\alpha_i$ for $i = 0, 1, 2$ (probability for a cell to die/migrate in each cell division), calculates as $\alpha_i = 1 - d_i - c_i$, decreased with increasing number of cell generations, suggesting a reduced probability to die/migrate.

A snapshot of the experimental relative frequencies for each cell generation and the relative frequencies predicted by the identified model are reported in Figure 4C showing a satisfactory quality of fit.
fit represented by the low discrepancy between the model relative frequencies and data.

In conclusion, the modeling analysis shows that the developed model is reliable and can be fruitfully exploited for predictive simulations and/or other possible purposes related to the study of primary T-cell activation.

Table 1. Number of OVA-specific CD4⁺ T cells and total lymphocytes.

| Route of immunization | Lymphoid organ | Time | OVA-specific T cells | Total Lymphocytes |
|-----------------------|----------------|------|---------------------|-------------------|
| Vaginal               | ILN            | 0    | 15.7±6.2            | 2303±925          |
|                       |                | 57   | 74.5±34.5           | 4383±1300         |
|                       |                | 72   | 106±64***           | 5017±2600         |
| CLN                   | 0              | 31.9±21 | 4264±1322          |                   |
|                       | 57              | 8.8±3.6 * | 3890±1190         |                   |
|                       | 72              | 16±9.1   | 4888±2400         |                   |
| SPL                   | 0              | 185.5±24.5 | 40748±11482      |                   |
|                       | 57              | 52.2±19 *** | 30052±5117      |                   |
|                       | 72              | 157±70    | 47902±35887       |                   |
| Nasal                 | CLN            | 0    | 31.9±21            | 4264±1322         |
|                       |                | 57   | 26±28              | 4832±1219         |
|                       |                | 72   | 79.5±47.6 *       | 7636±3777         |
| ILN                   | 0              | 15.7±6.2            | 2303±925          |
|                       | 57              | 1.7±0.7 ***       | 1909±541          |
|                       | 72              | 4.5±3.2 ***       | 1735±1059         |
| SPL                   | 0              | 185.5±24.5 | 40748±11482      |                   |
|                       | 57              | 68.2±16.4 *    | 47167±10180       |
|                       | 72              | 186.4±118        | 43000±15916       |

ILN: iliac lymph nodes (subiliac, medial and external); CLN: cervical lymph nodes (superficial and posterior); and SPL: spleen.

Absolute number of OVA-specific CD4⁺ T cells calculated as [(percentage of CD4⁺ CFSE⁺ x absolute number of lymphocytes)/100] for each lymphoid organ. OVA-specific T cells and total lymphocytes absolute numbers are to be multiplied ×10³.

One-way analysis of variance (ANOVA) and Tukey’s post test were used to compare the number of OVA-specific CD4⁺ T cells present in lymphoid organs at different time points.

*P<0.05; ***P<0.001.

doi:10.1371/journal.pone.0080545.t001

Antigen-specific transgenic T cells express activation and homing molecules

The phenotype of transgenic CD4⁺ T cells was assessed in draining lymph nodes three days following vaginal or nasal immunization. The expression of surface markers, in immunized or naïve mice, was analysed in each generation (from 0 to 6) identified by CFSE fluorescence intensity (Fig. 5A) and the respective MFI values were reported in Fig. 5B. The modulation of surface marker expression in transgenic CD4⁺ T cells was very

![Figure 3. Clonal expansion of OVA-specific CD4⁺ T cells following vaginal or nasal immunization.](image_url)
Proliferation of antigen-specific CD4+ T cells following treatment with isotype control or anti-CD62L antibody. Clonal division was assessed in draining lymph nodes 57 hours following immunization and analyzed as CFSE dilution (x axis) on the gated CFSE+ CD4+ populations with light scatter properties of lymphocytes.

C) Comparison of the experimental relative frequencies obtained from 5 mice at the time-point t = 57 h and the predicted values by the branching process for each cell generation following vaginal immunization.

doi:10.1371/journal.pone.0080545.g004

Figure 4. A Galton Watson branching process in the discrete time. A) Schematic representation of the stochastic behavior of the branching process. The i in the circle denotes the cell generation tracked with CFSE. Between two subsequent time-steps a single cell in i generation could take independently by the other cells, three biological decisions: entering in division with probability ⧺, dying with probability ⧺, and creating two cells of i+1 generation, resting undivided in generation i with probability ⧺. The formalism allows us to calculate the moments of cell counts. B) Proliferation of antigen-specific CD4+ T cells following treatment with isotype control or anti-CD62L antibody. Clonal division was assessed in draining lymph nodes 57 hours following immunization and analyzed as CFSE dilution (x axis) on the gated CFSE+ CD4+ populations with light scatter properties of lymphocytes. C) Comparison of the experimental relative frequencies obtained from 5 mice at the time-point t = 57 h and the predicted values by the branching process for each cell generation following vaginal immunization.

da0,0.380,03
\_d0,0150,0483
\_d1,0470,16
\_d1,0260,124
\_d2,0370,10
\_d2,0500,126
\_d0,0320,09
\_d0,0110,0432
\_d1,0400,13
\_d1,0210,11
\_d2,0550,18
\_d2,0250,146

Table 2. MGW process parameter estimates.

| Route  | Parameters | Values | Standard Deviation |
|--------|------------|--------|--------------------|
| Vaginal| c0         | 0.38   | 0.03               |
|        | d0         | 0.15   | 0.0483             |
|        | ?0         | 0.47   | 0.16               |
|        | ?1         | 0.26   | 0.124              |
|        | ?2         | 0.37   | 0.10               |
|        | ?2         | 0.50   | 0.126              |
| Nasal  | c0         | 0.32   | 0.09               |
|        | d0         | 0.11   | 0.0432             |
|        | d1         | 0.40   | 0.13               |
|        | ?1         | 0.21   | 0.11               |
|        | ?2         | 0.55   | 0.18               |
|        | ?2         | 0.25   | 0.146              |

Antigen-specific CD4+ T cells disseminate to distal lymphoid organs

OVA-specific CD4+ T-cell proliferation was analysed at different time points (0, 2.5, 3, 5, and 7 days) following vaginal or nasal immunization in the respective draining and distal lymph nodes and spleen. The kinetic analysis of the T-cell priming showed a rapid antigen-specific clonal division of transgenic CD4+ T cells in the respective draining lymph nodes already at day 2.5, with about 75% of proliferating transgenic T cells in iliac and 60% in cervical lymph nodes following vaginal or nasal immunization respectively (Fig. 6). Proliferation values were almost steady maintained at all analysed time points. The dissemination of proliferated T cells into distal lymph nodes started at day 3 and increased at day 5 with about 35% of vaginally primed T cells in distal cervical lymph nodes and 50% of nasally primed T cells in distal iliac lymph nodes (Fig. 6). The percentage of proliferated cells in the spleen was about 50% and 75% of transgenic T cells following vaginal and nasal immunization respectively (Fig. 6). Seven days after immunization, divided T cells were still detectable in distal lymph nodes and in the spleen. No significant differences in the percentage of T-cell proliferation were observed following vaginal and nasal immunization at any time-points analysed in draining and distal lymph nodes and spleen.

Discussion

In the present work antigen-specific CD4+ T-cell primary activation and dissemination following vaginal immunization was characterized and compared to the one elicited by the nasal route. The very early events of CD4+ T-cell clonal expansion following immunization by the two mucosal routes were analysed applying a Multi-type Galton Watson branching process. Understanding in depth the early events that lead to the immune response is crucial for the rational development of appropriate prime-boost vaccine strategies.

Following vaginal immunisation of mice treated with progesterone, antigen-bearing DCs were detected only in draining lymph nodes and not in distal lymph nodes or in the spleen, in line with what observed with nasal immunization [32]. In vaginally immunized mice, antigen-loaded DCs persisted in draining lymph nodes up to 72 hours while following nasal immunisation were detected only within 24 hours. The extended persistence following vaginal immunisation is probably due to the fact that mice were
immunized in the diestrous phase, when the antigen uptake is enhanced [17,19,48–50].

A recruitment of antigen-specific T cells from distal lymphoid sites was observed in draining lymph nodes with a simultaneous significant decrease of T cells in distal lymph nodes and in the spleen. Vaginal immunization of mice was more effective at stimulating antigen-specific CD4\(^+\) T-cell recall in draining lymph nodes compared to nasal immunization. The analysis of T-cell clonal expansion showed 5 cell generations, while at the same time-point 4 cell generations were detected in cervical lymph nodes following nasal immunization. These results are in line with what reported by Marks and colleagues showing higher frequency of antigen-specific T cells in draining iliac lymph nodes following vaginal respect to nasal immunization with OVA and cholera toxin [19]. This more rapid local T-cell proliferation following vaginal immunization can be due to the lack of an organized lymphoid tissue in the female genital tract. Indeed, upon vaginal immunization, iliac lymph nodes directly drain the genital mucosa [5], whereas following nasal vaccination antigen-specific T-cell proliferation first takes place in the NALT and then in cervical lymph nodes, as previously showed by our group and others [30,51]. The T-cell proliferation observed following vaginal immunization was strictly dependent on the estrous phase since no T-cell response was observed in estrogen treated mice. This is

Figure 5. Phenotypic analysis of proliferating antigen-specific CD4\(^+\) T cells. The expression of CD45RB, CD69, CD44 and CD62L was analysed as a function of cell divisions on OVA-specific CD4\(^+\) T cells from draining lymph nodes 72 hours following vaginal or nasal immunization with OVA and CpG ODN 1826. A). Dot plot analysis of CFSE dilution (x axis) versus CD45RB, CD69, CD44 and CD62L expression (y axis) on OVA-specific CD4\(^+\) T cells in naïve and vaginally or nasally immunised mice. B). Mean fluorescence intensity of CD45RB, CD69, CD44 and CD62L expression per each cell generation of OVA-specific CD4\(^+\) T cells from naïve mice (open histogram) and vaginally or nasally immunised mice (dark and light gray respectively). Cell divisions (from 0 to 6) are identified by CFSE intensity dilutions. Phenotypic analysis was performed on single mice. Results are representative of two experiments with six animals per group.

doi:10.1371/journal.pone.0080545.g005
clonal expansion of adoptively transferred CD4+ T cells following vaginal or nasal immunization with OVA plus CpG ODN 1826 was analyzed on days 2.5, 3, 5, and 7 post immunization in draining and distal lymph nodes and spleen. Values reported in y axis indicate the percentage of proliferating antigen-specific T cells. OVA-specific T cells were identified as CD4+ CFSE-positive populations, with light scatter properties of lymphocytes. The percentages of proliferating cells are shown on the y axis. Bars represent the means ± standard errors of the means (SEM) of values from nine mice assessed in three separate experiments.

doi:10.1371/journal.pone.0080545.g006

in accordance with previous studies reporting that immune response in the female genital tract depends upon the reproductive hormones [3,18,22,52].

To characterize in depth the antigen-specific T-cell clonal expansion in draining lymph nodes in the first hours following antigen administration, a mathematical model, based on the MGW branching process with immigration was exploited as a tool to estimate in vivo the probability of an antigen-specific CD4+ T cell to divide following the antigen-encounter. While this model has been previously applied for in vitro studies [38–40], it had not been previously applied to in vivo proliferation data. This is due to the fact that in vivo analysis raises several difficulties, mainly due to the fact that i) a lymph node is not an ‘isolated’ site but is part of a complex system and ii) data are collected from different animals introducing an inter-individual stochastic aspect. The impact of T-cell egress has been ruled out by carrying out the measurements, used for inference, at early time points (57 hours) when almost no T-cell has left the draining lymph node. Nevertheless, a significant recruitment of naive T cells from other lymphoid sites takes place over the measurement time horizon. To address this problem, the MGW model was generalized by adding an immigration term [46] calculated with an appropriate experiment where access of naive T cells was blocked through the treatment with the anti-CD62L antibody. Concerning the second point, model identification has been performed by using relative frequencies as variables instead of cell counts. This choice allowed us to derive an explicit expression for the Maximum Likelihood function for the MGW model since the distribution of relative frequencies at different time points is asymptotically normal, provided the number of initial cells starting the proliferation process is large [39]. The good quality of fit, represented by the low discrepancy between the model relative frequencies and experimental data, shows that the obtained model is reliable and can be therefore fruitfully exploited for predictive simulations and/or other possible purposes related to the study of primary T-cell activation. Model parameter estimates indicate that the probability of a cell to proliferate was higher following vaginal than nasal immunization, suggesting that the vaginal immunization route induces a higher CD4+ T-cell proliferation in draining lymph nodes with respect to the nasal route. Ongoing work is focused on modeling the whole complex immunological network, including both draining, distal lymph nodes and spleen, in order to get further quantitative information and create a model capable of predicting the intensity and distribution of T cells in the various lymphoid organs.

Proliferated antigen-specific CD4+ T cells were activated by the antigen encounter, as shown by the rapid expression of the early activation marker CD69 [53] and CD44 [54] within the very early cell generations. On the contrary, CD45RB, a marker expressed by naive T cells [55], was down-modulated as cell division proceeded. The expression of CD62L, a molecule essential for lymphocyte entry into lymph nodes [56], was gradually increased by proliferated T cells. The phenotypic analysis of antigen-specific proliferating CD4+ T cells in draining lymph nodes showed a similar modulation pattern of surface marker following vaginal and nasal immunization confirming that T cells were activated and able to disseminate into distal lymph nodes. These findings are in line with precedent data obtained following intranasal immunization with recombinant bacteria [29,31]. Despite T-cell recruitment and antigen-specific T-cell proliferation that was faster in draining lymph nodes following vaginal immunisation, no statistically significant differences in the percentage of antigen-specific proliferated CD4+ T cells were observed at later time-points (5 and 7 days) between vaginal and nasal immunization.

All together these data show that not only nasal but also vaginal immunization, despite the absence of an organized mucosal associated inductive site in the genital tract, is very efficient in priming antigen-specific CD4+ T cells in draining lymph nodes and inducing their dissemination from draining lymph nodes towards distal lymphoid organs.

Acknowledgments

The authors thank Anna Maria Cuppone for her technical assistance.

Author Contributions

Conceived and designed the experiments: DM EP AC AB AV G.Prota G.Pozzi. Performed the experiments: EP G.Prota FF AB. Analyzed the data: EP DM AC G.Prota AB AV. Wrote the paper: DM EP AV AB.

References

1. Harandi AM, Medaglini D (2010) Mucosal Adjuvants. Curr HIV Res 8: 330–335.

2. Holmgren J, Czerkinsky C (2003) Mucosal immunity and vaccines. Nature Medicine 11: 45–53.
3. Holmgren J, Svennerholm AM (2012) Vaccines against mucosal infections. Curr Opin Immunol 24: 343–353.

4. Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12: 592–605.

5. Pavot V, Rochereau N, Guénin C, Verrier B, Paul S (2012) New insights in mucosal vaccine development. Vaccine 30: 142–154.

6. Fujikawa Y, Tokohara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, et al. (2012) Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines 11: 367–379.

7. Mann JFS, McKay OR, Afokiasamy S, Patel RK, Tregenning JS, et al. (2013) Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. PLoS ONE 8: e67912.

8. Neutra MR, Kodrowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148–158.

9. Brandtzaeg P (2011) Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. Am J Respir Crit Care Med 183: 1595–1604.

10. Lehner T (2009) Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 19: 21–28.

11. Gherardi MM, Najera JL, Perez-Jimenez E, Guerra S, Garcia-Sastre A, et al. (2011) Inductive/effector mechanisms for humoral immunity at mucosal surfaces of the female reproductive tract: stratification and immune response magnitude. Immunity 27: 203–213.

12. Naz RK (2012) Female genital tract immunity: distinct immunological challenges for vaccine development. Adv Dent Res 19: 21–28.

13. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2009) Adoptive transfer of antigen-specific naive CD4+ and CD8+ T cells to study mucosal adjuvants. Methods 49: 491–500.

14. Warnock RA, Askari S, Butcher E, von Andrian UH (1998) Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J Virol 72: 7049–7057.

15. Pettini E, Ciabattini A, Pozzi G, Medaglini D (2009) Adjuvative transfer of antigen-specific naive CD4+ and CD8+ cells in the genital and intestinal tracts. Vaccine 28: 1226–1233.

16. Russel MW, Mestecky J (2002) Humoral immune responses to microbial infections. Microbes and Infection 4: 667–677.

17. Zuercher AW (2003) Upper respiratory tract immunity. Viral Immunol 16: 279–289.

18. Marks EM, Helgeby A, Andersson JO, Schon K, Lycke NY (2011) CD4+ T-cell priming in response to intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 187: 3386–3395.

19. Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR transgenic in transgenic mice constructed using cDNA-based alpha- and beta-defensins and TLRs. Immune Immunol 19: 121–131.

20. Wira CR, Fahey JV, Wira CR (2013) Mouse estrous cycle regulation of innate immunity in the female reproductive tract: the role of sexual cycles in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 63: 544–565.

21. Sceave MM, Mosemann TR (2009) Estradiol-induced vaginal mucus inhibits antigen presentation and CD4+ T cell priming in response to intravaginal immunization. Vaccine 27: 2342–2349.

22. Marks EM, Holgeby A, Anderson JO, Schön K, Lycke NY (2011) CD4+ T-cell immunity in the female genital tract is critically dependent on local mucosal immunity. Eur J Immunol 41: 2642–2653.

23. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2010) Intranasal vaccination with recombinant bacteria. Infect Immun 76: 5817–5825.

24. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2010) Intranasal vaccination with recombinant bacteria and CD4+ CD8+ T-cells in the genital tract. Vaccine 28: 1226–1233.

25. Moon JH, Cha HH, Pepper M, McSorley SJ, Jameson SC, et al. (2007) Naïve CD4(+) T-cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203–213.

26. Zuercher AW (2003) Upper respiratory tract immunity. Viral Immunol 16: 279–289.

27. Pettini E, Ciabattini A, Pozzi G, Medaglini D (2009) Adoptive transfer of antigen-specific naive CD4+ and CD8+ T cells to study mucosal adjuvants. Methods 49: 491–500.

28. Hawkins ED, Turner ML, Dowling MR, van Gend C, Hodijkin PD (2007) A model of immune regulation as a consequence of randomized lymphocyte division and death times. Proc Natl Acad Sci U S A 104: 5032–5037.

29. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, et al. (2007) Reconstruction of cell population dynamics using CFSE. BMC Bioinformatics 8.

30. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, et al. (2007) Reconstruction of cell population dynamics using CFSE. BMC Bioinformatics 8.

31. Ciabattini A, Pettini E, Andersen P, Pozzi G, Medaglini D (2008) Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria. Infect Immun 76: 5817–5825.

32. Medaglini D, Ciabattini A, Cappone AM, Costa C, Ricci S, et al. (2006) In vivo activation of naive CD4+ T-cells in mice by intranasal vaccination with recombinant Staphylococcus gordonii. Infect Immun 74: 2760–2766.

33. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2010) Intranasal immunization with recombinant Staphylococcus gordonii elicits primed CD4+ and CD8+ T cells in the genital and intestinal tracts. Vaccine 28: 1226–1233.

34. Ciabattini A, Pettini E, Fiorenza F, Prota G, Pozzi G, et al. (2011) Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice. PLoS ONE 6: e19346.

35. Pettini E, Ciabattini A, Pozzi G, Medaglini D (2009) Adoptive transfer of antigen-specific naive CD4+ and CD8+ T cells to study mucosal adjuvants. Methods 49: 491–500.

36. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2009) Adoptive transfer of antigen-specific naive CD4+ and CD8+ T cells to study mucosal adjuvants. Methods 49: 491–500.

37. Midlands Immuno: 27: 203–213.

38. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2009) Adoptive transfer of antigen-specific naive CD4+ and CD8+ T cells to study mucosal adjuvants. Methods 49: 491–500.

39. Ciabattini A, Pettini E, Arsenijevic S, Pozzi G, Medaglini D (2009) Adoptive transfer of antigen-specific naive CD4+ and CD8+ T cells to study mucosal adjuvants. Methods 49: 491–500.

40. Hyrien O, Chen R, Zand MS (2010) An age-dependent branching process model for the analysis of CFSE-labeling experiments. Biostatistics 5: 4–5.

41. Bode G, Zhao G, Steinhausen F, Kinjo T, Klimm DM (2011) CpG DNA as vaccine adjuvant. Expert Rev Vaccines 11: 367–379.

42. Davis SS (2001) Nasal vaccines. Adv Drug Deliv Rev 51: 21–42.

43. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

44. Bode G, Zhao G, Steinhausen F, Kinjo T, Klimm DM (2011) CpG DNA as vaccine adjuvant. Expert Rev Vaccines 11: 367–379.

45. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

46. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

47. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

48. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

49. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

50. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

51. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

52. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

53. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

54. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

55. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

56. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.

57. Athreya KB, Ney PE (1972) Branching processes. Dover Book on Mathematics.